Acute Effects of Glucose Dependent Insulinotropic Polypeptide (GIP) on Subcutaneous Adipose Tissue
Not Applicable
Completed
- Conditions
- Metabolic SyndromeObesityInsulin Sensitivity
- Registration Number
- NCT00774488
- Lead Sponsor
- German Institute of Human Nutrition
- Brief Summary
This clinical, randomized, cross-over study in obese healthy subjects aimed to analyse the acute effects of the incretin hormon Glucose Dependent Insulinotropic Polypeptide (GIP) on metabolic parameters and gene expression in subcutaneous adipose tissue.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 17
Inclusion Criteria
- BMI > 28
- Healthy subjects
- Normal glucose tolerance
Exclusion Criteria
- Diabetes,IFG, IGT
- Chronical-inflammatory diseases
- Hb < 12g/dl
- Elevation in liver enzymes or creatinin concentrations
- Great weight changes within last 12 months
- Any cancer diagnosis in last 10 years
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Changes in gene expression of subcutaneous adipose tissue with microarray analysis 3 years
- Secondary Outcome Measures
Name Time Method Analysis of inflammatory marker (blood levels and gene expression), Activity of 11beta HSD and 11-beta HSD mRNA in adipose tissue, etc. 3 years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms mediate GIP's acute effects on subcutaneous adipose tissue in obese individuals?
How does GIP compare to GLP-1 agonists in improving insulin sensitivity and metabolic parameters in obesity?
Which biomarkers correlate with GIP-induced metabolic changes in subcutaneous adipose tissue?
What adverse events are associated with GIP administration in obese subjects and how are they managed?
Are there synergistic effects of combining GIP with other incretin-based therapies for metabolic syndrome?